Citigroup’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $175K | Sell |
1,813
-4,943
| -73% | -$494K | ﹤0.01% | 4059 |
|
|
2025
Q4 | $657K | Buy |
6,756
+3,516
| +109% | +$302K | ﹤0.01% | 3415 |
|
|
2025
Q3 | $231K | Sell |
3,240
-1,184
| -27% | -$78.9K | ﹤0.01% | 3931 |
|
|
2025
Q2 | $265K | Sell |
4,424
-3,194
| -42% | -$175K | ﹤0.01% | 3933 |
|
|
2025
Q1 | $400K | Buy |
7,618
+750
| +11% | +$42.1K | ﹤0.01% | 3797 |
|
|
2024
Q4 | $378K | Buy |
6,868
+1,027
| +18% | +$54K | ﹤0.01% | 4020 |
|
|
2024
Q3 | $294K | Buy |
5,841
+804
| +16% | +$37.1K | ﹤0.01% | 4087 |
|
|
2024
Q2 | $221K | Buy |
5,037
+772
| +18% | +$32.8K | ﹤0.01% | 3829 |
|
|
2024
Q1 | $188K | Buy |
4,265
+3,200
| +300% | +$141K | ﹤0.01% | 4050 |
|
|
2023
Q4 | $50.6K | Buy |
1,065
+1,048
| +6,165% | +$44.1K | ﹤0.01% | 4514 |
|
|
2023
Q3 | $754 | Sell |
17
-2,158
| -99% | -$100K | ﹤0.01% | 5140 |
|
|
2023
Q2 | $104K | Buy |
2,175
+2,174
| +217,400% | +$98K | ﹤0.01% | 4233 |
|
|
2023
Q1 | $39 | Sell |
1
-384
| -100% | -$14K | ﹤0.01% | 5343 |
|
|
2022
Q4 | $10.9K | Buy |
385
+150
| +64% | +$4.29K | ﹤0.01% | 4811 |
|
|
2022
Q3 | $7K | Sell |
235
-405
| -63% | -$14.1K | ﹤0.01% | 5113 |
|
|
2022
Q2 | $22K | Sell |
640
-260
| -29% | -$9.32K | ﹤0.01% | 4941 |
|
|
2022
Q1 | $40K | Sell |
900
-716
| -44% | -$33.1K | ﹤0.01% | 4823 |
|
|
2021
Q4 | $75K | Buy |
1,616
+891
| +123% | +$35.9K | ﹤0.01% | 4879 |
|
|
2021
Q3 | $24K | Buy |
725
+404
| +126% | +$13.7K | ﹤0.01% | 5154 |
|
|
2021
Q2 | $9K | Sell |
321
-71
| -18% | -$1.96K | ﹤0.01% | 5699 |
|
|
2021
Q1 | $10K | Sell |
392
-708
| -64% | -$16.9K | ﹤0.01% | 5645 |
|
|
2020
Q4 | $25K | Buy |
1,100
+818
| +290% | +$18.9K | ﹤0.01% | 6506 |
|
|
2020
Q3 | $6K | Sell |
282
-484
| -63% | -$10.9K | ﹤0.01% | 6906 |
|
|
2020
Q2 | $18K | Sell |
766
-1,065
| -58% | -$22.9K | ﹤0.01% | 6699 |
|
|
2020
Q1 | $39K | Buy |
1,831
+919
| +101% | +$21.9K | ﹤0.01% | 6196 |
|
|
2019
Q4 | $21K | Buy |
912
+404
| +80% | +$9.44K | ﹤0.01% | 6913 |
|
|
2019
Q3 | $11K | Sell |
508
-728
| -59% | -$14.9K | ﹤0.01% | 7025 |
|
|
2019
Q2 | $25K | Buy |
1,236
+259
| +27% | +$6.1K | ﹤0.01% | 6965 |
|
|
2019
Q1 | $27K | Buy |
977
+208
| +27% | +$5.44K | ﹤0.01% | 6789 |
|
|
2018
Q4 | $19K | Sell |
769
-194
| -20% | -$5.21K | ﹤0.01% | 6899 |
|
|
2018
Q3 | $36K | Buy |
963
+459
| +91% | +$12.4K | ﹤0.01% | 6771 |
|
|
2018
Q2 | $10K | Buy |
+504
| New | +$8.91K | ﹤0.01% | 7190 |
|
|
2017
Q4 | – | Sell |
-3,631
| Closed | -$35K | – | 7597 |
|
|
2017
Q3 | $35K | Sell |
3,631
-12,451
| -77% | -$118K | ﹤0.01% | 6171 |
|
|
2017
Q2 | $138K | Buy |
16,082
+5,418
| +51% | +$46.2K | ﹤0.01% | 5092 |
|
|
2017
Q1 | $95K | Sell |
10,664
-6,439
| -38% | -$59.7K | ﹤0.01% | 5248 |
|
|
2016
Q4 | $190K | Buy |
17,103
+16,771
| +5,052% | +$181K | ﹤0.01% | 5319 |
|
|
2016
Q3 | $6K | Sell |
332
-74
| -18% | -$1.37K | ﹤0.01% | 6711 |
|
|
2016
Q2 | $9K | Sell |
406
-1,606
| -80% | -$28.9K | ﹤0.01% | 6596 |
|
|
2016
Q1 | $38K | Buy |
2,012
+1,989
| +8,648% | +$38.1K | ﹤0.01% | 6247 |
|
|
2015
Q4 | $1K | Sell |
23
-39
| -63% | -$1.1K | ﹤0.01% | 7381 |
|
|
2015
Q3 | $1K | Buy |
62
+25
| +68% | +$598 | ﹤0.01% | 7172 |
|
|
2015
Q2 | $1K | Buy |
+37
| New | +$676 | ﹤0.01% | 7302 |
|
Other funds holding IRMD
CCM
VCM
NTCM
Citigroup's IRMD Position: Q1 2026 in Review
Citigroup reduced its iRadimed (IRMD) stake by 73% in Q1 2026, selling an estimated $494K and leaving 1,813 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #4059.
Citigroup first reported a position in IRMD in Q2 2015 and has held it in 42 quarters since. The position peaked at $657K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Citigroup held 1,813 shares of iRadimed worth $175K as of Q1 2026.
- Citigroup sold 4,943 iRadimed shares in Q1 2026, an estimated $494K.
- iRadimed made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4059 holding.
- Citigroup first reported a position in iRadimed in Q2 2015 and has held it in 42 quarters since.
- Citigroup's iRadimed position peaked at $657K in Q4 2025.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.